0
0.0
Jul 2, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
-- it's lilly and biogen that seem to be leading here. the question is, what's the size of this market? there's different estimates. and the estimates will probably grow, when you think about the addressable market. alzheimer's is kind of its own, i guess focused treatment, but there may be other reasons that we think that it could be contributing, that could be contributing to alzheimer's. 5 billion addressable market, is that enough for what we think maybe -- i don't know what people think has been priced into lilly at this point, but there's no question, alzheimer's has been a big part of the lilly move. >>> the presidential election about four months away, will drug prices be the new battleground for the candidates? let's bring in chris meekens, health care policy analyst. great to have you with us. was this the op-ed today, was that just political rhetoric, or do you think there is something to be concerned about if you are a health care investors? >> look, i think that if democrats sweep, they told you what they're going to do, whic
-- it's lilly and biogen that seem to be leading here. the question is, what's the size of this market? there's different estimates. and the estimates will probably grow, when you think about the addressable market. alzheimer's is kind of its own, i guess focused treatment, but there may be other reasons that we think that it could be contributing, that could be contributing to alzheimer's. 5 billion addressable market, is that enough for what we think maybe -- i don't know what people think...
0
0.0
Jul 8, 2024
07/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
abigail: eli lilly is up .4%.ypically don't have the acquirer higher, but more if it is up 75%, close to the price they offered. $3.2 billion in cash, about $57 per share. the fact that the stock is there, folks think the deal will be done. interesting that eli lilly investors are putting a stamp of approval on it. it broadens them out. the company has got-related science. eli lilly has been doing great but they are in immunology, every percent of their revenue. this will broaden them out to some degree in that area with some early-stage trials which their ceo says wants to start making those kinds of deals. scarlet: interesting that eli lilly makes the deal not long after the ceo talking about how he didn't need to make a splashy purpose -- purchase. abigail: i would argue it is not so splashy. it is for those that own morphic but it is a $2 billion market cap company. early-stage developmental, one selective molecule inhibitor for ibd. it is being used in three clinical trials, two in ulcerative colitis, one in
abigail: eli lilly is up .4%.ypically don't have the acquirer higher, but more if it is up 75%, close to the price they offered. $3.2 billion in cash, about $57 per share. the fact that the stock is there, folks think the deal will be done. interesting that eli lilly investors are putting a stamp of approval on it. it broadens them out. the company has got-related science. eli lilly has been doing great but they are in immunology, every percent of their revenue. this will broaden them out to...
0
0.0
Jul 8, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
lilly's drug is just too good. while we know it works on sleep apnea, weight loss and diabetes, the biggest indication, probably heart problems and blood pressure are yet to come. that's not all lilly is doing. right now it's gotten approval for a drug that slows the progression of alzheimer's disease, long considered impossible the take on, because luna is safe for many people. this is according to my own sources and the brain in my community. we don't know the size of this market. we just know sadly it's growing like a weed, and this drug is one of two hopes, the other being from biogen. and now lilly takes the cash disappearing from its coffers and buys morphic for $3.2 billion, fulfilling a promise to find new drugs. that's a 79% premium. i know that seems a lot. but lilly needs to focus on the burgeoning immeteorology with a pill to help manage ibs and crohn's disease. these are largest and growing diseases, some of the fastest out there sadly. what lilly has done is get behind a drug that might be more potent
lilly's drug is just too good. while we know it works on sleep apnea, weight loss and diabetes, the biggest indication, probably heart problems and blood pressure are yet to come. that's not all lilly is doing. right now it's gotten approval for a drug that slows the progression of alzheimer's disease, long considered impossible the take on, because luna is safe for many people. this is according to my own sources and the brain in my community. we don't know the size of this market. we just...
0
0.0
Jul 17, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
i think lilly and novo are years ahead. they have the most money. they continue to innovate, probably better, faster than any of the other players, and they're going to have different modalities, different drugs they bring to market. probably before a roche, before a pfizer. so, i'm not incredibly worried about the competition, but yeah, any time you have two companies with this sort of lead and there's any sort of conversation at all that others could kind of penetrate that market, you're going to see share weakness. >> part of this is a rotation, right? just into -- the rotation that's going on in the broader markets in total, right? >> for sure. yeah, today the -- >> pfizer is turning around. >> that's crazy. >> your pfizer. >> i know. >> 30 handle for the first time. >> yeah, pfizer up a lot, bristol almost up 5% at one point today. so, you are getting a value and you're getting an underperformer rotation, which is kind of synonymous at this point, concurrent with this news, it kind of all set up for these -- for lilly and novo to underperform t
i think lilly and novo are years ahead. they have the most money. they continue to innovate, probably better, faster than any of the other players, and they're going to have different modalities, different drugs they bring to market. probably before a roche, before a pfizer. so, i'm not incredibly worried about the competition, but yeah, any time you have two companies with this sort of lead and there's any sort of conversation at all that others could kind of penetrate that market, you're...
0
0.0
Jul 25, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
lilly has lost $120 billion in market cap from its highs. and of course you have to think of this whole rotation that's going on from sort of the so-called high flyers, richer valuation stocks to the more value-oriented areas of the market. this is getting swept up in addition to all these headlines about newer competitors entering the market. >> tim has brought this up and dan, they are trading like technology stocks. we've tried to say incorrectly for a period of time that eli lilly specifically was getting really expensive on a number of different metrics, not least of which their market cap compared to the earnings revenue they're going to see next year, which is historic in terms of big cap pharma. it's getting a bit more reasonable now, but i don't see any compelling reason to go jumping into lily here ahead of earnings. i think it's august 8th. unfortunately i still think there's room to the downside. >> to your point, especially with the competition coming, and there's going to be pressure on pricing too, right? if you think about th
lilly has lost $120 billion in market cap from its highs. and of course you have to think of this whole rotation that's going on from sort of the so-called high flyers, richer valuation stocks to the more value-oriented areas of the market. this is getting swept up in addition to all these headlines about newer competitors entering the market. >> tim has brought this up and dan, they are trading like technology stocks. we've tried to say incorrectly for a period of time that eli lilly...
0
0.0
Jul 1, 2024
07/24
by
BBCNEWS
tv
eye 0
favorite 0
quote 0
the boss of us pharma giant eli lilly addresses concerns, as generic weight—loss drugs become more accessiblehello and welcome to business today. i'm steve lai. as we kick off a new month and the official start of the second half of 2024, let's recap some of the key challenges the global economy faced over the past six months. in the us, the federal reserve has not provided much clarity on lowering the cost of borrowing as the economy grapples with a major cost of living crisis. china's growth recovery is also concerning amid a persistent property crisis and soft domestic consumption. added to that are geopolitical tensions with wars in ukraine and the middle east fuelling global uncertainty. i spoke with jameel ahmad, chief analyst at gtc group, about what to look out for in the second half of the year. i would say it was unprecedented because it was like adding everything into your shopping basket. if you look at the s&p 500, it hit new record highs more than 30 times. those are the type of records that, to use a metaphor, that cristiano ronaldo would be jealous of in his trophy cabinet. it
the boss of us pharma giant eli lilly addresses concerns, as generic weight—loss drugs become more accessiblehello and welcome to business today. i'm steve lai. as we kick off a new month and the official start of the second half of 2024, let's recap some of the key challenges the global economy faced over the past six months. in the us, the federal reserve has not provided much clarity on lowering the cost of borrowing as the economy grapples with a major cost of living crisis. china's...
0
0.0
Jul 8, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >> well, lilly has a -- a drug. i was surprised that lilly was up five. that was silly today.ve an immunological portfolio where they're doing clinical trials on the diseases that these guys are using a pill to control, and maybe it's just better to go spend $3.2 billion. >> that's nothing for lilly. we're talking ulcerative colitis, phase two study in crohn's disease. phase two studies in ulcerative colitis and one phase two study in crohn's. that's where morphic is focused. >> abbvie does have a good product in this space. >> when lilly comes into something now, i give them the benefit of the doubt. >> you have to. >> because they are alone. they are alone, jim. as they approach $900 billion market value, lilly's market cap is twice that of its next competitor. >> when the stock was at $400 billion, told you -- >> j&j and the $354 billion market value. >> j&j has a talc issue. eli lilly, last i looked, has a problem that people are losing too much weight. >> merck, $322 billion. these guys -- i don't know. they're buying this thing for a big premium and it gets them into a n
. >> well, lilly has a -- a drug. i was surprised that lilly was up five. that was silly today.ve an immunological portfolio where they're doing clinical trials on the diseases that these guys are using a pill to control, and maybe it's just better to go spend $3.2 billion. >> that's nothing for lilly. we're talking ulcerative colitis, phase two study in crohn's disease. phase two studies in ulcerative colitis and one phase two study in crohn's. that's where morphic is focused....
0
0.0
tv
eye 0
favorite 0
quote 0
morphic, that is the company that eli lilly has made a bid for. an all-time high right now. look at this gain, 75% higher to $55 and change after eli lilly agreed to buy the bio pharmaceutical company in a $3.2 billion deal. lilly said it will pay $57 a share to boost its immunotherapy product offerings. morphic develops oral integrin treatments which are easier to take than injectables for chronic diseases including cancer, inflammatory bowel diseases like krones and colitis and the deal is expected to close in the third quarter. eli lilly is also moving higher to $915.88 which is an all-time record here. we have morphic at the moment at $55.76 so just a buck or so below the asking price that lilly has offered there. different story with service now shares are coming off a pretty ugly session but still down 5% heading back down to the lows after guggenheim downgraded the cloud software company to sell from neutral over potential risks on the horizon, so what does guggenheim see? well in the second half of the year analyst john difucci says servic
morphic, that is the company that eli lilly has made a bid for. an all-time high right now. look at this gain, 75% higher to $55 and change after eli lilly agreed to buy the bio pharmaceutical company in a $3.2 billion deal. lilly said it will pay $57 a share to boost its immunotherapy product offerings. morphic develops oral integrin treatments which are easier to take than injectables for chronic diseases including cancer, inflammatory bowel diseases like krones and colitis and the deal is...
0
0.0
Jul 25, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
we own eli lilly. and let's remind people that lilly has very similar products. someone should go buy viking. if i were pfizer, i would buy viking, but i would buy it because you want to compete, and it's worth it, but this is not going to hurt lilly longer term, because it takes billions of dollars to build the plants, and they're -- lilly's got the same product. this would be a me too kill but theirs is once a month. we're not sure the duration of -- is it once a week for lilly? we need to know from lilly, and i don't have that source -- i don't have the sourcing to be able to check to see what lilly has. nobody else does either. >> lot of movers on them. here's another positive one that we haven't hit yet is raytheon, or i should say rtx. rtx, very strong results that are being g-- getting a very positive response in the market. reported sales, up 8% versus the prior year. they say 10% on what they call an organic basis. gap eps, 8 cents, including 29 cents of acquisition. accounting adjustments and
we own eli lilly. and let's remind people that lilly has very similar products. someone should go buy viking. if i were pfizer, i would buy viking, but i would buy it because you want to compete, and it's worth it, but this is not going to hurt lilly longer term, because it takes billions of dollars to build the plants, and they're -- lilly's got the same product. this would be a me too kill but theirs is once a month. we're not sure the duration of -- is it once a week for lilly? we need to...
0
0.0
Jul 23, 2024
07/24
by
BELARUSTV
tv
eye 0
favorite 0
quote 0
, yes, i know, lilly has left, i will give you the money, follow me.hat you should introduce each other. with sofia, she got used to you, and then you decided to give birth to a child for us, so you decided nothing could be changed, now it doesn’t matter, yes, indeed, nothing can be changed now, the amount is large, so why pay attention to the little things, but what did you want, i really need money, it’s true, that’s it, listen, i should have just asked for it, and not sold my body, especially children, then why, i can’t understand why you made an audio recording and were hysterical, then make sure that the police got this recording so that i would divorce her, yes, and you married me, so what, what are you saying, i i don’t know anything at all about the police, or about the recording, or about the divorce, let go of my hand, it hurts, and i will never don't suit me anymore. wow, this is for me, where did so much come from? i received this money. let's go to. i received this money for becoming a surrogate mother for a tailor’s child, what did you sa
, yes, i know, lilly has left, i will give you the money, follow me.hat you should introduce each other. with sofia, she got used to you, and then you decided to give birth to a child for us, so you decided nothing could be changed, now it doesn’t matter, yes, indeed, nothing can be changed now, the amount is large, so why pay attention to the little things, but what did you want, i really need money, it’s true, that’s it, listen, i should have just asked for it, and not sold my body,...
0
0.0
Jul 10, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
i nominate lilly as the next to join the $1 trillion club. second, berkshire hathaway, a close second. just under $893 billion. i could easily see this one crossing the trillion dollar barrier. a lot of moving parts here. mosaic ensuring geico. apple is a swing factor here. and the monster massage position here. a lot of industrial exposure. they could go over a trillion dollars. what will need lower interest rates as they seem convinced that lower rates will help the stock save the technology names, even as i would argue that's not going to go higher regardless of the interface. there is always where intrepidation. and the top two could easily be surpassed by the real wild card of the group. if we get one more surge in the stock of the unsinkable tesla, which has been up for 11 straight days. now these days tesla is being pitched more of a technology company than automaker. they just needed to demonstrate the tesla energy could become a much bigger piece of the business. we know tesla's vehicle sales are leveling off after period of decline.
i nominate lilly as the next to join the $1 trillion club. second, berkshire hathaway, a close second. just under $893 billion. i could easily see this one crossing the trillion dollar barrier. a lot of moving parts here. mosaic ensuring geico. apple is a swing factor here. and the monster massage position here. a lot of industrial exposure. they could go over a trillion dollars. what will need lower interest rates as they seem convinced that lower rates will help the stock save the technology...
0
0.0
Jul 2, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
let's start with eli lilly today.ed. should that dent the share's near term potential? >> it's a great buying opportunity. eli lilly is looeder in this sp. they have multiyear, multi-investment opportunities. i think these, you know, these drugs are here to stay. of course, the best way to play is lilly. any dip is great. >> in this case? it's doubled over the past year. you don't think it's too expensive? >> it's too expensive in the near term. five years forward where they will have this massive global scale, obesity is a global problem, not just a u.s. problem and the amount of revenue they will generate tauf this product is going to be tremendous. if you have a three to five-year forecast going forward, a vision going forward, you will be well served from lilly. >> what if prices get capped? >> i think it may actually expand the markets. you have lower prices, maybe you have more people willing to take the drug. there is a huge demand. they can't fill it. from everything i see, three to five, sometimes six-week wa
let's start with eli lilly today.ed. should that dent the share's near term potential? >> it's a great buying opportunity. eli lilly is looeder in this sp. they have multiyear, multi-investment opportunities. i think these, you know, these drugs are here to stay. of course, the best way to play is lilly. any dip is great. >> in this case? it's doubled over the past year. you don't think it's too expensive? >> it's too expensive in the near term. five years forward where they...
0
0.0
Jul 24, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
that is almost as big as an entire eli lilly. so, is this just the start of the great rotation out of big tech? how much more pain still could come, guy? >> i mean -- 356, 2% move? see, i thought that would happen 256 days ago, but we're finally -- so, but here we are. okay. >> only off by one. >> a little bit. it's all good. so, you look at a couple things. we traded down today, we held -- we closed right at the 50-day moving average in the s&p 500, which is encouraging. we closed at an uptrend line that's been in tact for a better part of the year. a similar thing happened in april in terms of the 50-day. that's encouraging. here's what's not entirely encouraging in terms of where we traded down. the fact that ten-year yields went higher today and happened late in the day is something that the market should absolutely look at. ten-year yields closed north of 4.28%. one would think that on a risk-off day like this you'd see a flight to quality in the bond market. you did not. i think it's encouraging we traded down to and held t
that is almost as big as an entire eli lilly. so, is this just the start of the great rotation out of big tech? how much more pain still could come, guy? >> i mean -- 356, 2% move? see, i thought that would happen 256 days ago, but we're finally -- so, but here we are. okay. >> only off by one. >> a little bit. it's all good. so, you look at a couple things. we traded down today, we held -- we closed right at the 50-day moving average in the s&p 500, which is encouraging....
0
0.0
Jul 8, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
and eli lilly climbing to new heights.rs when "fast money" returns. >>> missed a moment of "fast?" catch us any time on the go. follow the "fast money" podcast. we're back right after this. [crowd chanting] they ignored your potential, and mocked your ambition. but it's not the critic who counts. with every swing and block, your game plan never changed. ♪♪ some still call it luck. let them. because you know what it's always been. inevitable. ♪♪ ♪♪ >>> welcome back to "fast money." the s&p and nasdaq closing at fresh record highs to kick off the week. the dow feel about 30 points. paramount lower today after agreeing to merge with sky dance media, ending months of negotiations and marking an end to the redstone family's control of the media giant. a group that includes private equity firms red bird capital and kkr whether invest $8 billion as part of this deal. >>> president biden insisting to democratic law makers he is staying in the race. but will there be more pressure on his re-election campaign as congress comes back
and eli lilly climbing to new heights.rs when "fast money" returns. >>> missed a moment of "fast?" catch us any time on the go. follow the "fast money" podcast. we're back right after this. [crowd chanting] they ignored your potential, and mocked your ambition. but it's not the critic who counts. with every swing and block, your game plan never changed. ♪♪ some still call it luck. let them. because you know what it's always been. inevitable. ♪♪...
0
0.0
Jul 10, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
with lilly, tesla. >> lilly, i think, is $900. >> lilly is under nine. >> we mentioned barclay's goingaro beats. >> how many plants can you build? how quickly? these are $5 billion plants. they are very hard to make, and in the meantime, all that happens is people say they might have a pill. believe me, david ricks, ceo of eli lilly, is going to be first with a pill too. and now they securichanged the . they've changed a lot of names. >> the alzheimer's drug. >> very important. >> could be yet another potential blockbuster for the company >> a lot of people, because i do this stuff with the american brain foundation, american migraine, a lot of people feel this really does forestall or make it so that alzheimer's -- put it off a couple years. >> that's conceivably a very important, and a game-changer. will the federal government pay for it? medicare is already stressed. >> i was talking with people about what would turn eli lilly into an absolute sure, and it is everything hard, which is still the biggest killer in our country. everything cardio that it does. really remarkable. how abo
with lilly, tesla. >> lilly, i think, is $900. >> lilly is under nine. >> we mentioned barclay's goingaro beats. >> how many plants can you build? how quickly? these are $5 billion plants. they are very hard to make, and in the meantime, all that happens is people say they might have a pill. believe me, david ricks, ceo of eli lilly, is going to be first with a pill too. and now they securichanged the . they've changed a lot of names. >> the alzheimer's drug....
0
0.0
Jul 18, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
so let me tell you where i come out on the magnificent seven plus eli lilly bear cases. every one of these bear cases is for real just like most of the bearish arguments you've been hearing about these stocks for years now. at a certain point, though, real worries do get baked in. the market is trying hard to bake these in. you can own losers and have no profit taking. right? winners have profit taking that's what's happening. do i know when they'll bottom? do i know when they're done? usually when you ask that you're staring at the bottom. but i felt yesterday was going to be the last day of the sell-off and that was wrong. but if you ask me, the reason why these former winners are all going down now is because the shareholders are scared. they're frightened they don't want to give up their gains. so they're getting out why don't i feel similarly inclined because bottom line i think if you're willing to own them for the long haul and take some pain you'll continue to win you just need to get over the hump a hump that periodically scares people out of this whole asset cl
so let me tell you where i come out on the magnificent seven plus eli lilly bear cases. every one of these bear cases is for real just like most of the bearish arguments you've been hearing about these stocks for years now. at a certain point, though, real worries do get baked in. the market is trying hard to bake these in. you can own losers and have no profit taking. right? winners have profit taking that's what's happening. do i know when they'll bottom? do i know when they're done? usually...
0
0.0
Jul 18, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
>> can we get the disclaimers on eli lilly? >> i'm not involved. >> great.ust to clarify for transparency. thank you for joining us this morning. that was emily field, head of the european research at barclays. >>> coming up on the show, we are looking at tsmc. they blew past the second quarter expectations. we will break down the numbers lu the sector drops halfhe t vae. vae.what is cirkul? cirkul is the fuel you need to take flight. cirkul is your frosted treat with a sweet kick of confidence. cirkul is the energy that gets you to the next level. cirkul is what you hope for when life tosses lemons your way. cirkul is your gateway back home. so what is cirkul? it's your water, your way. cirkul, available at walmart and drinkcirkul.com. when we're young, we're told anything is possible... ...but only a few of us go out and prove it. witness the greatness of anna hall on a connection worthy of gold: xfinity mobile. only xfinity gives you the most powerful mobile wifi network, with speeds up to a gig in millions of locations. and right now, get up to $800 off
>> can we get the disclaimers on eli lilly? >> i'm not involved. >> great.ust to clarify for transparency. thank you for joining us this morning. that was emily field, head of the european research at barclays. >>> coming up on the show, we are looking at tsmc. they blew past the second quarter expectations. we will break down the numbers lu the sector drops halfhe t vae. vae.what is cirkul? cirkul is the fuel you need to take flight. cirkul is your frosted treat with...
0
0.0
Jul 9, 2024
07/24
by
KSTS
tv
eye 0
favorite 0
quote 0
las medicinas que producen novo nordisk tienen un compuesto diferente a los de eli lilly, y segÚn estecias. gracias, aranza. una joven tenista hispana hoy puede decir sÍ se pudo y estÁ inspirando a otros a soÑar su historia de superaciÓn al volver, quÉ desea? >> arranca tu dÍa bien informado con noticias telemundo. ahora la actualidad mÁs relevante para ti en vivo desde el lugar de los hechos. >> una jornada, sin duda histÓrica. >> todo lo que necesitas saber ah (♪♪) your pain shouldn't be minimized or forgotten. (♪♪) when medicine gets better, all of us can get better. (música de ópera) (♪♪) (♪♪) (♪♪) (♪♪) (♪♪) vives para encontrar la paz interior. vivimos para monitorear precios de vuelos al paraíso. ¿por qué los dermatólogos de todo el mundo recomiendan la roche-posay? cuida tu piel con la loción hidratante facial “la roche-posay double repair face moisturizer” con su doble acción que ayuda a reparar la barrera de la piel y proporciona 48 horas de hidratación para lucir una piel saludable. depend te mantiene más seca que nunca para que puedas decir “yes” más que nunca. yes. yes. yes
las medicinas que producen novo nordisk tienen un compuesto diferente a los de eli lilly, y segÚn estecias. gracias, aranza. una joven tenista hispana hoy puede decir sÍ se pudo y estÁ inspirando a otros a soÑar su historia de superaciÓn al volver, quÉ desea? >> arranca tu dÍa bien informado con noticias telemundo. ahora la actualidad mÁs relevante para ti en vivo desde el lugar de los hechos. >> una jornada, sin duda histÓrica. >> todo lo que necesitas saber ah...
0
0.0
Jul 18, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
a lot of leaders i about on halftime, i own that eli lilly. >> chip pot lay is down. >> i think what tells it all is the vix. it's certainly higher than it's been over the last three months, at the highest level since april. we probably have the blossoming of a much-needed correction. maybe it's a remind tore investors that a broader market or one that's not anchored by a handful of huge stocks is not necessarily in the near term a more stable westbound or more predictable. how do you think investors should be reacting to it, if at all. >> i see this as the healthy correction in a broader up trend. as you said, we're coming into season at weakness august and september sort of never fade to disappoint on the index level. ultimately, i think to go forward structural, the large caps are going to take over here, simply because there's not enough market cap to absorb the total rotation if you just look at the top ten stocks of the s&p, they're 5 1/2 times of the market cap of the russell. the s&p itself is 15 times the market cap of the russell, so it's a bit like putting an elephant thro
a lot of leaders i about on halftime, i own that eli lilly. >> chip pot lay is down. >> i think what tells it all is the vix. it's certainly higher than it's been over the last three months, at the highest level since april. we probably have the blossoming of a much-needed correction. maybe it's a remind tore investors that a broader market or one that's not anchored by a handful of huge stocks is not necessarily in the near term a more stable westbound or more predictable. how do...
0
0.0
Jul 11, 2024
07/24
by
CNBC
tv
eye 0
favorite 0
quote 0
>> lilly is the leader here and we're expecting phase three data from them next year.hat's the furthest along, and pfizer, a little bit ago at the goldman sachs health care conference, was saying they see lilly as the leader, them as next and then astrazeneca. those are separated by a few years, so it is a crowded market, and there is a lead there for lilly, but pfizer still thinks they have a role here. >> definitely trying to play some catch-up today. thank you. angelica peebles. >>> still to come the growth of evs and the ai boom. a look at how some power companies are dealing with this massive surge in demand. >>> coming up on "money movers" this morning former nec director and goldman director gary cohn. we will break down today's cpi number and look forward to the big bank earnings moow ttorrhat begins at 11:00 a.m. eastern time. stay with us. >>> shares of costco giving up gains. the company raising its membership fee for the first time since 2017. annual memberships are going up by $5 in the u.s. and in canada. higher tiered plans will increase by $10. the stoc
>> lilly is the leader here and we're expecting phase three data from them next year.hat's the furthest along, and pfizer, a little bit ago at the goldman sachs health care conference, was saying they see lilly as the leader, them as next and then astrazeneca. those are separated by a few years, so it is a crowded market, and there is a lead there for lilly, but pfizer still thinks they have a role here. >> definitely trying to play some catch-up today. thank you. angelica peebles....
0
0.0
Jul 2, 2024
07/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
on the equity side, nova notice and eli lilly shares -- novo nordisk and eli lilly shares down. the president says it companies no lower prices, "we will do everything in our power to end it for them." shares down about 2% now on the day. we are watching paramount shares moving on a report that barry diller, who led paramount decades ago is considering a bid for the entertainment giant. he was chairman of the digital media company iac. according to the report, diller has signed nda's with national amusements. paramount now up almost 2%. the big news of the day, earlier today jay powell spoke at the euro central bank forum in portugal. inflation is getting back on a downward path but he remains patient. take a listen. chair powell: they want to be confident inflation is moving towards 2% before we start the process of reducing how tight our policy is of loosening policy. because the u.s. economy is strong, the market is strong, we have the ability to take our time and get this right. that is what we are planning to do. sonali: we will discuss the comments with michael mckee becau
on the equity side, nova notice and eli lilly shares -- novo nordisk and eli lilly shares down. the president says it companies no lower prices, "we will do everything in our power to end it for them." shares down about 2% now on the day. we are watching paramount shares moving on a report that barry diller, who led paramount decades ago is considering a bid for the entertainment giant. he was chairman of the digital media company iac. according to the report, diller has signed nda's...
0
0.0
Jul 13, 2024
07/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
we know of eli lilly, and amgen could be a competitor.nd so this is i guess a crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one or two million of those today. so there is a huge market opportunity here, and there is a place for more. and you are right. in most markets, when you get more competition and also, over time, pricing moves down, because you start treating those who accept, say, the higher price point -- in the u.s., that is commercial insurance -- and, over time, you get broader access and you get patients paying a lower price. if you just take our leading diabetes product in the u.s., since launch in 2018, the price we get after rebates, discounts, etc., is some 40% lower than when we launched. that is often not mentioned in, say, the political debate. instead, the list price
we know of eli lilly, and amgen could be a competitor.nd so this is i guess a crucial time when you have to make investment decisions, when prices are high and you have more cash coming in. is that how you view it? lars: yes. to put a bit of color around it, the same forecast predicts that there will be, say, a billion people living with obesity in 3035. we are perhaps serving one or two million of those today. so there is a huge market opportunity here, and there is a place for more. and you...
0
0.0
tv
eye 0
favorite 0
quote 0
we have been following your trades along with eli lilly which is in the news.ppenheimer came out yesterday we're upping our target to 5900. do we get there? do we see some type of black swan that spooks the horses? tell me. >> at this point keybanc went to 180. that means they're going for 1800. people thought i was nuts at beginning of year when i said 12, 1400. here we are post-split about 130. i don't think for the next month nvidia is the place to be. i think it will be a consolidation period. remember on june 20th, we talked about the overcrowded semiconductor top and pulled in almost 15 to 20% from there? i do think there is a healthy rotation. i think the megacap tech did a great job while semis were consolidating. amazon got to 200. apple get to 225. new highs on google and microsoft. this market has been moving up very strategically. now the whole conversation is, can we finally get a get a bit f rebalance trade of small caps and bios. i think there is a chance of that. i think tech is overheated. i think the gains for the rest of the summer will be mu
we have been following your trades along with eli lilly which is in the news.ppenheimer came out yesterday we're upping our target to 5900. do we get there? do we see some type of black swan that spooks the horses? tell me. >> at this point keybanc went to 180. that means they're going for 1800. people thought i was nuts at beginning of year when i said 12, 1400. here we are post-split about 130. i don't think for the next month nvidia is the place to be. i think it will be a...
0
0.0
Jul 3, 2024
07/24
by
KSTS
tv
eye 0
favorite 0
quote 0
mab esto es de la farmacÉutica y la lilly y se venderÁ bajo el nombre de cÁpsula en ensayos clÍnicos. el medicamento. >> el donante mab es un anticuerpo monoclonal y lo que hace es que marca el amiloide que se estÁ acumulando de una manera anormal en unas placas en el en las cÉlulas del cerebro y al marcarlo eso permite que la propia el propio sistema inmunolÓgico, en particular las microglÍas, limpien el amiloide del cerebro. >> este medicamento se inyecta mensualmente y es muy probable que medicare lo cubra, que es solo para aquellos pacientes cuyo alzheimer estÁ en una etapa temprana. es momento de hacer una pausa en el mundo, un evento religioso resulta mortal. en india, las protestas en nairobi y seguridad en el rÍo sena para y seguridad en el rÍo sena para los juos este viaje... ¿lo recuerdas? ¿vamos papá? sí claro, con mi rodilla... (♪♪) (♪♪) entonces papá, ¿seguimos la tradición? vive a la altura de toda aventura. el completamente nuevo lexus gx. (♪♪) ¿buscas una razón para probar el nuevo $5 meal deal de mcdonald's? aquí tienes una... dos... tres... cuatro... y con el precio
mab esto es de la farmacÉutica y la lilly y se venderÁ bajo el nombre de cÁpsula en ensayos clÍnicos. el medicamento. >> el donante mab es un anticuerpo monoclonal y lo que hace es que marca el amiloide que se estÁ acumulando de una manera anormal en unas placas en el en las cÉlulas del cerebro y al marcarlo eso permite que la propia el propio sistema inmunolÓgico, en particular las microglÍas, limpien el amiloide del cerebro. >> este medicamento se inyecta mensualmente y es...
0
0.0
Jul 3, 2024
07/24
by
KPIX
tv
eye 0
favorite 0
quote 0
the agency approved kisunlu produced by eli lilly.r's. the drug is only the second that's been convincingly shown to delay cognitive decline in patients. eli lilly says a year's worth of therapy would cost around $32,000. >>> in other health news, the fda will no longer allow the use of an additive found in some sodas. it's called bvo, and it's used in small amounts to keep citrus flavoring from floating to the top of beverages. bvo has been linked to health ailments including nervous system damage and loss of muscle coordination and memory. the ban takes effect in august. >>> and anti-depressants have gotten a bad rap for causinga weight gain, but a new study finds some are more likely it ard on the pounds than others. patients using lexapro, paxil, and cymbalta were 10% to 15% more likely to gain at least 5% of their baseline weight than zoloft users. those taking wellbutrin were 15% less likely to gain weight than zoloft users. and patients on prozac were not associated with a weight change at all. >>> coming up on "cbs mornings,"
the agency approved kisunlu produced by eli lilly.r's. the drug is only the second that's been convincingly shown to delay cognitive decline in patients. eli lilly says a year's worth of therapy would cost around $32,000. >>> in other health news, the fda will no longer allow the use of an additive found in some sodas. it's called bvo, and it's used in small amounts to keep citrus flavoring from floating to the top of beverages. bvo has been linked to health ailments including nervous...
0
0.0
tv
eye 0
favorite 0
quote 0
this would lead to the university of toronto, partnering with eli lilly and company to become the 1st to manufacturer and so much as a life saving treatment of diabetes. the today much of the world's insulin production comes from one of 3 companies. eli lilly saying that fee for novo, nor disk i like to call hypoglycemia and insulin overdose. right? so if you're eating a high car meal, you need a high dose. eventually you're applying a balancing act. mean it's high car is high dose of insulin and sometimes you roll the dice and you, you hit it, but most of the times you're going to be off one way or the other. you know, this isn't an option on medicine. this isn't a vitamin or something that will help with allergies. this is light saving. if our children don't have insulin, they die. that's what happened to kids. before insulin came around, you did your best to limit carbohydrates, but their blood sugars were high, they wasted away and they died. when i was diagnosed at 9 years old, i remember i was about 35 pounds. if you see any of those pictures that going way back to like before,
this would lead to the university of toronto, partnering with eli lilly and company to become the 1st to manufacturer and so much as a life saving treatment of diabetes. the today much of the world's insulin production comes from one of 3 companies. eli lilly saying that fee for novo, nor disk i like to call hypoglycemia and insulin overdose. right? so if you're eating a high car meal, you need a high dose. eventually you're applying a balancing act. mean it's high car is high dose of insulin...
0
0.0
tv
eye 0
favorite 0
quote 0
this would lead to the university of toronto, partnering with eli lilly and company to become the 1st to manufacturer. and so as a life saving treatment of diabetes, the today much of the world's insulin production comes from one of 3 companies. eli lilly saying that fee for novo, nor disk. i like to call april garcia and into an overdose. right? so if you're eating a high car, you know, you need a high dose. eventually you're playing a balancing act between his high car and it's high dose of insulin. and sometimes you roll the dice and you, you hit it, but most of the time you're going to be off one way or the other. or, you know, this isn't an option on medicine. this isn't a vitamin or something that will help with allergies. this is life saving. if our children don't have insulin, they die. that's what happened to kids. before, insulin came around, you did your best to limit carbohydrates, but their blood sugars were high, they wasted away and they died. when i was diagnosed at 9 years old, i remember i was about 35 pounds. if you see any of those pictures that going way back to r
this would lead to the university of toronto, partnering with eli lilly and company to become the 1st to manufacturer. and so as a life saving treatment of diabetes, the today much of the world's insulin production comes from one of 3 companies. eli lilly saying that fee for novo, nor disk. i like to call april garcia and into an overdose. right? so if you're eating a high car, you know, you need a high dose. eventually you're playing a balancing act between his high car and it's high dose of...